| Autor: |
Tran, AH, Best, BM, Stek, A, Wang, J, Capparelli, EV, Burchett, SK, Kreitchmann, R, Rungruengthanakit, K, George, K, Cressey, TR, Chakhtoura, N, Smith, E, Shapiro, DE, Mirochnick, M, Buschur, S, Jackson, C, Paul, M, McGregor, D, Yogev, R, Kalra, R, Florez, C, Bryan, P, Stone, M, Hull, AD, Caffery, M, Spector, SA, Wilson, J, Giner, J, Donnelly, MA, Cooper, ER, McLaud, DA, Tucker, LF, Hitti, J, Robson-Nuss, A, Melvin, AJ, Keller, MA, Bolaris, MA, Hayes, J, Kamer, F, Spencer, LS, Homans, J, Metz, T, Wallace, J, Katai, A, Aziz, M, McNichols, M, Schmidt, J, Wara, D, Maka, K, Cohan, D, Deveikis, A, Batra, J, Alvarez, JJ, Carter, M, Deville, J, Janzen, C, Gutierrez, J, Cavallo, M, Purswani, M, Knapp, KM, Sublette, N, Wride, T |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Zdroj: |
Tran, AH; Best, BM; Stek, A; Wang, J; Capparelli, EV; Burchett, SK; et al.(2016). Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. Journal of Acquired Immune Deficiency Syndromes, 72(3), 289-296. doi: 10.1097/QAI.0000000000000968. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/8jd889qr |
| Popis: |
© Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved. Background: Rilpivirine pharmacokinetics is defined by its absorption, distribution, metabolism, and excretion. Pregnancy can affect these factors by changes in cardiac output, protein binding, volume of distribution, and cytochrome P450 (CYP) 3A4 activity. Rilpivirine is metabolized by CYP3A4. The impact of pregnancy on rilpivirine pharmacokinetics is largely unknown. Methods: International Maternal Pediatric Adolescent AIDS Clinical Trials P1026s is a multicenter, nonblinded, prospective study evaluating antiretroviral pharmacokinetics in HIV-infected pregnant women that included a cohort receiving rilpivirine 25 mg once daily as part of their combination antiretrovirals for clinical care. Thirty-two women were enrolled in this study. Intensive pharmacokinetic sampling was performed at steady state during the second trimester, the third trimester, and postpartum. Maternal and umbilical cord blood samples were obtained at delivery. Plasma rilpivirine concentration was measured using liquid chromatography-mass spectrometry; lower limit of quantitation was 10 ng/mL. Results: Median (range) AUC0-24 were 1969 (867-4987, n 15), 1669 (556-4312, n 28), and 2387 (188-6736, n 28) ng·h/mL in the second trimester, the third trimester, and postpartum, respectively (P < 0.05 for either trimester vs postpartum). Median (range) C24 were 63 (37-225, n 17), 56 ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
